Dr. Rita Basu, MD., is a tenured Professor in the Division of Endocrinology, department of Medicine at the University of Virginia (UVA) School Of Medicine. She received her medical degree from Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER) in Pondicherry, India. In 1996, she joined the Mayo Clinic in Rochester, MN as a trainee investigator in integrative physiology of Diabetes and other metabolic disorders. Following completion of her fellowship in 1999 she continued her career in understanding the pathophysiology and mechanisms of insulin resistance in humans with metabolic disorders and rapidly rose through the ranks to a full Professor in the Division of Endocrinology at the Mayo Clinic in 2012. She was recruited to the UVA faculty (fall 2017) as part of a strategic initiative to develop Translational research for diabetes at UVA School of Medicine and Center for Diabetes Technology (CDT). She currently serves as the Clinical Education Director of the CDT.

Dr. Basu is currently the Principal Investigator on grants from NIH as well as industry. These include studies that probe the mechanisms of hepatic and peripheral insulin resistance in humans with type 2 diabetes and pre-diabetes. Dr. Basu is also a co-investigator on several NIH sponsored projects for the artificial pancreas for type 1 diabetes.

Dr. Basu has had a long and productive career as an expert in the Ethics of Research and Human subject protection for over a decade at Mayo Clinic where she served as Chair of the Mayo Clinic IRB for over 10 years. She is currently the Chair of the Health Sciences IRB at the University of Virginia.

At UVA, she has continued to develop state of the art physiology and interventional research to better phenotype people with type 2 diabetes, NAFLD/NASH and pre-diabetes such that therapy to treat these disorders could be more precise and personalized, targeting the specific physiological abnormalities in a person-specific manner to match the national and NIDDK call for ‘Precision Medicine’ initiative.

Her educational interests include teaching providers and patients to effectively manage and optimize glycemic control by using state of the art technological devices. Towards this, she Chairs CME/CNE credited “Diabetes technology symposiums” both at UVA and in national meetings. She has several grants related to educational initiatives for training primary care physicians, nurses, and diabetes nurse educators, pharmacists on use of diabetes technology to improve care of patients with diabetes both within and outside USA.

She served on the American Diabetes association scientific sessions committee for 4 years. Her knowledge of evolving strategies for management of fatty liver disease has not gone unrecognized. She recently represented the Endocrine Society at a Senate Capitol Hill briefing on NASH and serves on the NASH steering committee established by the Chronic Liver Disease Foundation. She is a member of the Global Liver institute. She is currently working with peers from AACE in drafting the practice committee guideline recommendations for NAFLD/NASH. Furthermore, she adds voice to a patient advocacy group task force for NASH (ICER).

Dr. Basu has authored > 200 peer-review publications in major journals including the New England Journal of Medicine, Diabetes Care and Diabetes. She is on the editorial board of Diabetes Care, American Journal of Physiology and past Associate editor of the Diabetes Technology and Therapeutics journal. She serves as reviewer on numerous scientific associations and journals. She serves on several study sections of the National Institute of Health and International review panels and DSMB’s. She has actively participated as a WHO fellow and Co-Director in a WHO collaborating center initiated 5-year international program that provided advanced training and education to several hundred promising diabetologists in China and Europe.
She continues her commitment to excellence in diabetes training, education and research in her current position at UVA.

Professor Mazze is currently the director of the AGP Clinical Academy at Portsmouth University Hospitals, NHST, Portsmouth UK. He was formerly Head of the WHO Collaborating Centre for Diabetes Translation, a joint program of the International Diabetes Center (IDC) and Mayo Clinic as well as professor at the University of Minnesota Medical School. He is also visiting professor at Nanjing Medical University where he helped to develop a new research and training center devoted to diabetes modeled after the IDC. Previously he served as Professor and Executive Director of the Diabetes Research and Training Center at the Albert Einstein College of Medicine. There he developed the first WHO designated center for technology in diabetes. After moving to the IDC, Dr. Mazze initiated training programs in more than 40 countries based on a systematic evidence-based approach known as Staged Diabetes Management (SDM). The author of more than 100 original articles and several books, he is recognized as the the creator of the Ambulatory Glucose Profile (AGP) analytic program for continuous glucose monitoring and as the developer of the first memory-based reflectance meters. In recognition of these accomplishments, in 2017 the American Diabetes Association presented Dr. Mazze with the Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes. He is also the recipient of the 2021 DMDEA Gold Medal Oration Award, India.